Concepedia

Xu Zhu

XZ

Statistics

Publications

2

Citations

57

H-Index

2

Active since

2021

Affiliations

Novartis (United States)(Current)

Xu Zhu is an author at Novartis (United States).

Publications per year

2021–2021

2

Publications

2

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Ian W. Flinn, Ulrich Jaeger, Nirav N. Shah et al. · Blood · 2021 · 29 citations

Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Boris Engels, Xu Zhu, Jennifer Yang et al. · Blood · 2021 · 28 citations

1–2 of 2